Prognostic value of the triglyceride–glucose index in patients with premature acute coronary syndrome
- 1Shandong Second Medical University
- 2Department of Cardiology, Qingdao Municipal Hospital, University of Health and Rehabilitation Sciences
Abstract
Background The triglyceride-glucose (TyG) index has been proposed as an accessible indicator of insulin resistance and cardiometabolic risk. However, its prognostic relevance in patients with premature acute coronary syndrome has not been well defined. We therefore examined baseline clinical features and long-term cardiovascular outcomes in patients with premature acute coronary syndrome (PACS) stratified by TyG status. Methods This retrospective cohort study screened 820 consecutive patients hospitalized with PACS, of whom 804 had complete fasting triglyceride and fasting plasma glucose measurements for TyG calculation. TyG was calculated as ln [fasting triglycerides (mg/dL) × fasting plasma glucose (mg/dL) / 2]. Patients were categorized into high and low TyG groups using the 66.7th percentile as the cutoff. The primary outcome was major adverse cardiovascular and cerebrovascular events (MACCE). Results Among 804 eligible patients, 268 (33.3%) were assigned to the high TyG group and 536 (66.7%) to the low TyG group. Patients with high TyG showed a more unfavorable cardiometabolic profile and a higher coronary disease burden at baseline than those with low TyG. During follow-up, MACCE occurred in 17.2% of patients in the high TyG group and in 10.4% of those in the low TyG group. After multivariable adjustment, high TyG remained associated with a higher risk of MACCE (adjusted HR 1.61, 95% CI 1.05–2.47; P = 0.029). TyG analyzed as a standardized continuous variable was also independently associated with MACCE (adjusted HR 1.306, 95% CI 1.039–1.643; P = 0.022). Landmark analysis indicated that the association was more prominent after 365 days. Conclusion In this PACS cohort, elevated TyG was independently associated with an increased risk of MACCE, particularly during longer-term follow-up. TyG may provide a simple adjunctive marker for identifying residual cardiometabolic risk in relatively young patients after ACS.
Related
- Combined Triglyceride–High-density Lipoprotein Cholesterol Phenotypes and Cardiovascular Outcomes in Japanese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights from Clinical Deep Data Accumulation System-PCI
- Prognostic value of the C-reactive protein-triglyceride-glucose index (CTI) for major adverse cardiovascular events in patients with coronary artery disease: a retrospective cohort study
- Development and Population-Based Prognostic Utility Assessment of an ICD-10-CM-Based Prediction Model to Identify Left Ventricular Systolic Dysfunction: Discrimination Performance and Population-Based Evaluation in 83,357 Patients with Acute Coronary Syndrome
- Prognostic Impact of COVID-19 on Patients With Acute Coronary Syndrome Undergoing Emergent Percutaneous Coronary Intervention ― Insights From the J-PCI Nationwide Registry ―
- Association of the C-reactive protein–triglyceride–glucose index with adverse cardiovascular outcomes in patients with acute coronary syndrome and type 2 diabetes: findings from an observational cohort study in China
BibTeX
@article{sun2026prognostic,
title = {{Prognostic value of the triglyceride–glucose index in patients with premature acute coronary syndrome}},
author = {Yifan Sun and Jibin Chen and Nianzu Wei and Ming Zhang and Chunquan Zhang and Wei Xia and Lei Zhang and Yibing Shao and Bin Wang},
journal = {BMC Cardiovascular Disorders},
year = {2026},
month = jul,
doi = {10.1186/s12872-026-06263-0},
url = {https://doi.org/10.1186/s12872-026-06263-0},
note = {CC BY},
}
RIS
TY - JOUR
TI - Prognostic value of the triglyceride–glucose index in patients with premature acute coronary syndrome
AU - Yifan Sun
AU - Jibin Chen
AU - Nianzu Wei
AU - Ming Zhang
AU - Chunquan Zhang
AU - Wei Xia
AU - Lei Zhang
AU - Yibing Shao
AU - Bin Wang
PY - 2026
DA - 2026/07/01
JO - BMC Cardiovascular Disorders
DO - 10.1186/s12872-026-06263-0
UR - https://doi.org/10.1186/s12872-026-06263-0
AB - Background The triglyceride-glucose (TyG) index has been proposed as an accessible indicator of insulin resistance and cardiometabolic risk. However, its prognostic relevance in patients with premature acute coronary syndrome has not been well defined. We therefore examined baseline clinical features and long-term cardiovascular outcomes in patients with premature acute coronary syndrome (PACS) stratified by TyG status. Methods This retrospective cohort study screened 820 consecutive patients hospitalized with PACS, of whom 804 had complete fasting triglyceride and fasting plasma glucose measurements for TyG calculation. TyG was calculated as ln [fasting triglycerides (mg/dL) × fasting plasma glucose (mg/dL) / 2]. Patients were categorized into high and low TyG groups using the 66.7th percentile as the cutoff. The primary outcome was major adverse cardiovascular and cerebrovascular events (MACCE). Results Among 804 eligible patients, 268 (33.3%) were assigned to the high TyG group and 536 (66.7%) to the low TyG group. Patients with high TyG showed a more unfavorable cardiometabolic profile and a higher coronary disease burden at baseline than those with low TyG. During follow-up, MACCE occurred in 17.2% of patients in the high TyG group and in 10.4% of those in the low TyG group. After multivariable adjustment, high TyG remained associated with a higher risk of MACCE (adjusted HR 1.61, 95% CI 1.05–2.47; P = 0.029). TyG analyzed as a standardized continuous variable was also independently associated with MACCE (adjusted HR 1.306, 95% CI 1.039–1.643; P = 0.022). Landmark analysis indicated that the association was more prominent after 365 days. Conclusion In this PACS cohort, elevated TyG was independently associated with an increased risk of MACCE, particularly during longer-term follow-up. TyG may provide a simple adjunctive marker for identifying residual cardiometabolic risk in relatively young patients after ACS.
SN - 1471-2261
ER -